• The Journal of the Korea Contents Association
• /
• v.17 no.6
• /
• pp.632-642
• /
• 2017

The purpose of this study was to determine influence factors for predicting postoperative nausea and vomiting(PONV) for postoperative 24hr. Participants were 332 general surgery(GS), neurosurgery(NS), orthopedic surgery(OS), obstetrics and gynecology(OBGY), otorhinolaryngology (ENT) surgical patients at one hospital in G city. Data were collected from December 2014 to December 2015, and the data were analyzed by t-test, $x^2$-test and logistic regression analysis. Multivariate analysis revealed that non smoking (p=.011), history of motion sickness (p=.020), history of PONV (p=.001), post operative pain (p=.001) were influence factors for PONV. Preoperative intensive management of PONV is necessary if there is a history of non smoker, history of motion sickness and history of PONV before surgery, and postoperative pain should be actively intervened.

• The Journal of Korean Obstetrics and Gynecology
• /
• v.22 no.2
• /
• pp.209-221
• /
• 2009

목 적: 이 논문은 제왕절개 분만을 위한 척수마취로 인해 수술 중 또는 그 후에 발생할 수 있는 오심 및 구토에 대한 침관련 치료의 항구토 효과를 규명하기 위한 계통적 리뷰 논문이다. 방 법: 제왕절개 분만을 위한 척수마취로 인해 발생할 수 있는 오심 및 구토를 예방하기 위한 침관련 치료에 대한 randomized clinical trials(RCT's)를 검색하기 위해 2008년 3월까지 수록된 6개의 데이터베이스(MEDLINE, EMBASE, The Cochrane Library, CINAHL, AMED and PsycINFO)를 검색하였다. 논문의 선정 기준은 원저이며, 플라시보 대조군을 설정한 무작위 임상시험이고, 오심 또는 구토에 대한 결과가 실려 있는 것으로 하였다. 결 과: 총 5개의 논문을 선정하였으며 각 논문들의 연구방법은 일반적으로 좋은 편이었다. 5개의 논문들을 종합한 결과는 수술중 오심 발생률(OR=0.468, 95%CI:0.250 -0.876, P=0.018), 수술 후 오심 발생률(OR=0.616, 95%CI:0.042-0.942, P=0.026), 수술 후 구토 발생률(OR=0.640, 95%CI:0.432-0.948, P=0.026)이 침관련 치료군이 대조군에 비해서 통계적으로 의미있게 적었다. 결 론: 본 문헌 고찰을 통해 제왕절개 수술을 위해 시행한 척수 마취로 인해 수술중 또는 수술후 발생한 오심 및 구토에 대해 침관련 치료가 예방효과가 있음을 밝힐 수 있었다.

• Radiation Oncology Journal
• /
• v.19 no.2
• /
• pp.127-135
• /
• 2001

Purpose : This study is a prospective randomized clinical trial comparing the efficacy and complication of anti-emetic drugs for prevention of nausea and vomiting after radiotherapy which has moderate emetogenic potential. The aim of this study was to investigate whether the anti-emetic efficacy of ondansetron $(Zofran^{\circledR})$ 8 mg bid dose (Group O) is better than the efficacy of metoclopramide 5 mg lid dose (Group M) in patients undergoing fractionated radiotherapy to the abdominal region. Materials and Methods : Study entry was restricted to those patients who met the following eligibility criteria: histologically confirmed malignant disease; no distant metastasis; performance status of not more than ECOG grade 2; no previous chemotherapy and radiotherapy. Between March 1997 and February 1998, 60 patients enrolled in this study. All patients signed a written statement of informed consent prior to enrollment. Blinding was maintained by dosing identical number of tablets including one dose of matching placebo for Group O. The extent of nausea, appetite loss, and the number of emetic episodes were recorded everyday using diary card. The mean score of nausea, appetite loss and the mean number of emetic episodes were obtained in a weekly interval. Results : Prescription error occurred in one patient. And diary cards have not returned in 3 patients due to premature refusal of treatment. Card from one patient was excluded from the analysis because she had a history of treatment for neurosis. As a result, the analysis consisted of 55 patients. Patient characteristics and radiotherapy characteristics were similar except mean age was $52.9{\pm}11.2$ in group M, $46.5{\pm}9.5$ in group O. The difference of age was statistically significant. The mean score of nausea, appetite loss and emetic episodes in a weekly interval was higher in group M than O. In group M, the symptoms were most significant at 5th week. In a panel data analysis using mixed procedure, treatment group was only significant factor detecting the difference of weekly score for all three symptoms. Ondansetron $(Zofran^{\circledR})$ 8 mg bid dose and metoclopramide 5 mg lid dose were well tolerated without significant side effects. There were no clinically important changes In vital signs or clinical laboratory parameters with either drug. Conclusion : Concerning the fact that patients with younger age have higher emetogenic potential, there are possibilities that age difference between two treatment groups lowered the statistical power of analysis. There were significant difference favoring ondansetron group with respect to the severity of nausea, vomiting and loss of appetite. We concluded that ondansetron is more effective anti-emetic agents in the control of radiotherapy-induced nausea, vomiting, loss of appetite without significant toxicity, compared with commonly used drug, i.e., metoclopramide. However, there were patients suffering emesis despite the administration of ondansetron. The possible strategies to improve the prevention and the treatment of radiotherapy-induced emesis must be further studied.

• Journal of Hospice and Palliative Care
• /
• v.7 no.2
• /
• pp.248-257
• /
• 2004

Purpose: To evaluate the efficacy of dolasetron mesylate in controlling nausea and vomiting in the first 24 hours and to extend these comparisons over the next 4 days in patients receiving moderately emetogenic chemotherapy. Methods: This was a single center, open-labeled study with single arm. Dolasetron (1.8 mg/kg) was given intravenously (I.V.) prechemotherapy with 10 mg of dexamethasone IV, followed 24 hours later by oral dolasetron (200 mg once daily) for the subsequent 4 days. The frequency of vomiting, severity of nausea and the presence of rescue antiemetics were assessed daily. Results: Of 30 patients enrolled, 28 were eligible and evaluable for the efficacy. Four out of 28 patients had complete control of nausea and vomiting without any rescue antiemetics through 5 days. The complete control got better as time went by with the rates of 17.9/46.4/42.9/53.6/60.7% on days 1 to 5. Vomiting was better controlled than nausea in both cisplatin-containing and non-containing chemotherapy. The adverse events were mild to moderate degrees of headache, diarrhea and fever, but were recovered spontaneously. Conclusion: Dolasetron was effective and safe for the control of nausea and vomiting in the patients with moderately emetogenic chemotherapeutic agents.

• Radiation Oncology Journal
• /
• v.17 no.2
• /
• pp.141-145
• /
• 1999

Purpose : Granisetron is a potent, the most selective 5-HT3 receptor antagonist and is reported to b effective in treatment of radiation-induced emesis. The antiemetic efficacy and safety of oral granisteron was evaluated in patients with receiving highly emetogenic treatment by conventional fractionated irradiation. Materials and Methods : Patients with various cancers who were being treated with irradiation were accrued into the present study. The intensity of nausea was evaluated on first 24 hours and on day-7 by patients according to the degree of interference with normal daily life as followings; a) none; b) present but no interference with normal daily life (mild): c) interference with normal daily life (moderate): and d) bedridden because of nausea (severe). Non or mild state was considered to indicate successful treatment. The efficacy of antiemetic treatment was graded as follows; a) complete response; no vomiting, no worse than mild nausea and receive no rescue antiemetic therapy over the 24h period, b) major response; either one episode of vomiting or moderate/severe nausea or had received rescue medication over 24h period, or any combination of these, c) minor response; two to four episodes of vomiting over the 24h period, regardless of nausea and rescue medication, d) failure; more than four medication. The score of the most symptom was recorded and the total score over 24 hours was summarized. The complete or major response was considered to indicate successful treatment. Results : A total of 10 patients were enrolled into this study, and all were assessable for efficacy analysis. Total nausea control was achieved in 90$\%$ (9/10:none=60$\%$ plus mild=30$\%$) of total patients after 7 days. The control of vomiting by granisteron was noted in seven patients (70$\%$) of complete response and three (30$\%$) of major response with a hundred-percent successful treatment over 7 days. The minor response or treatment failure were not observed. No significant adverse events or toxicities from granisetron were recorded in patient receiving granisetron. Conclusion : We concluded that granisetron is a highly effective antiemetic agent in controlling radiotherapy-induced nausea or vomiting with a minimal toxicity profile.

• The Journal of Korean Medicine
• /
• v.17 no.2 s.32
• /
• pp.331-336
• /
• 1996

We have studied the effect of auricular acupuncture on postoperative nausea and vomiting (PONV). 100 female patients undergoing transabdominal hysterectomy were entered into the study. The patients were divided into two groups (auricular acupuncture treatment group and non-treatment group) to test the effectiveness of auricular acupuncture. acupuncture consisted of needle insertion in one ear at four points: sympathetic, stomach, shinmoon and occiput. Before the operation, the above points were punctured perpendicularly by the thumbtack-type needle, leaving its handle lying flat on the skin surface. There was no significant difference in age, weight, height and duration of anesthesia among the two groups of patients. There was a cignificant difference between the control group and auricular acupuncture treatment group in the incidence of vomiting at the first 12 h after surgery 68% and 30%, respectively, p<0.01) No noteworthy side effects fbom treatment were observed. auricular acupuncture is effective in reducing nausea and vomiting after transabdominal hysterectomy in female patients.

• Journal of Internet Computing and Services
• /
• v.12 no.1
• /
• pp.131-139
• /
• 2011

The purpose of this research is to evaluate patient's satisfaction and clinician' knowledge level about pain, nausea, vomiting, and temperature management of patients after operation by develop an web-based evidence-based practice guideline about pain, nausea, vomiting, and temperature control after operation in order to apply the guideline operation patients. The collected data was analyzed through real number, average, standard deviation, t-test and repeated ANOVA by using SPSS/WIN 17.0 program. The study subjects showed a significant difference in the level of knowledge about pain, nausea/vomiting, and temperature control after operation and patient's satisfaction, before and after applying the web-based evidence-based practice guideline.

• 대한두경부종양학회:학술대회논문집
• /
• 1991.11a
• /
• pp.8.2-10
• /
• 1991

• Korean Journal of Adult Nursing
• /
• v.23 no.4
• /
• pp.340-350
• /
• 2011

Purpose: This study was designed to analyze the characteristics and effect size of published intervention studies related to nausea & vomiting among cancer patients. Methods: A total of 1,083 studies were retrieved. From these studies, 20 studies met the inclusion criteria with a total of 698 participants. Two authors independently extracted data from the selected studies and assessed the methodological quality. The data were analyzed by the RevMan 5.0 program of Cochrane library. Results: The twenty studies utilized various non-pharmacological interventions: Nine studies on acupuncture (45%), Five studies utilized massage (25%), Two studies used oral cryotherapy (10%) and Four studies used other therapies. In the twenty studies the effect size of the intervention studies reported a higher effect sizes for massage (d=-1.62) and acupuncture (d=-0.89). Conclusion: This study suggests that non-drug therapy can reduce the levels of nausea and vomiting intensity. Massage and acupuncture interventions studies were more numerous and this may account for the higher effect rate.

• Journal of Korean Academy of Nursing
• /
• v.17 no.3
• /
• pp.195-203
• /
• 1987

Twenty five cancer patients were assigned to two groups: The experimental group which received Progressive Muscle Relaxation (PMR) training and the control group without the training. Base line data for dependent variables -nausea and vomiting, state anxiety and symptom distress- were collected when the subjects of both groups received the first cycle chemotherapy. Then the experimental group was trained for PMR between the first and the second cycle chemotherapy. The same dependent variables were measured during the second cycle chemotherapy from the subjects. Results indicated that the PMR group showed no significant difference in severity of nausea and vomiting compared to the control group. Although the significance was not supported, the severity of nausea and vomiting in experimental group decreased while control group increased between the first and fifth day of the second cycle chemotherapy. The experimental group showed significantly less state anxiety during the second cycle than the control group (p＜0.01). Significantly low symptom distress was also reported in the experimental group compared to the control group(p<0.01). The result suggests that PMR training may be an effective procedure for helping cancer patients cope with the adverse effects of their chemotherapy.